• Your search
    starts here.

    Whether you're looking for answers or a second opinion, put one of the world's leading cancer care centers to work for you.


    Search adult cancer typesSearch pediatric cancer types  

    Make an appointment
    with our care specialists.

    Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

    Adult 877-442-3324

    Pediatric 888-733-4662

    Make an Appointment Online  
  • flex image

    Innovation

    Ground-breaking research
    starts on our grounds.

    For 70 years, we’ve led the world by making life-changing breakthroughs in cancer research and patient care. Each year, patients cross the globe to receive the most advanced care available, including over 700 innovative clinical trials. Our sole mission is to defeat cancer, especially yours.

    Research at dana-farber
    Find a Clinical Trial  

Newsroom

Robert Haddad, MD

Some head and neck cancer patients benefit from continued checkpoint inhibitor treatment

April 3, 2017

New research suggests that some patients with head and neck cancers can benefit by continuing treatment with an immunotherapy drug after their tumors show signs of enlargement, according to investigators at Dana-Farber Cancer Institute.

 

Blog

stem cells illustration

Autologous vs. Allogenic Stem Cell Transplants: What's the Difference?

Two of the most common types of stem cell transplants are autologous and allogeneic transplants. Both kinds of stem cell transplantations are a common treatment option for cancers such as leukemia, lymphoma, and multiple myeloma.

 

Research

Precision Cancer Medicine - Nikhil Wagle, MD

Online Resource for Precision Cancer Medicine

Clinicians at Dana-Farber/Brigham and Women's Cancer Center are now armed with specialized tests to create a precise "tumor profile" for each patient's cancer. Learn about the latest thinking in precision cancer medicine from our researchers and clinicians, and explore a searchable database of clinical trials that focus on targeted therapies by disease, gene, and mutation.